Scarica l'app Stockscreener
1.55
4.73%
0.07
Pre-mercato:
1.60
0.05
+3.23%
Lineage Cell Therapeutics Inc Borsa (LCTX) Ultime notizie
B. Riley Financial Issues Positive Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - MarketBeat
ETF Watch: Is Lineage Cell Therapeutics Inc a top pick in the sector2026 Review & Precise Swing Trade Entry Alerts - baoquankhu1.vn
If You Invested $1,000 in Lineage Cell The (LCTX) - Stock Titan
LCTX: HC Wainwright Reiterates Buy Rating with $9 Price Target | - GuruFocus
HC Wainwright Reiterates Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Cell Therapeutics unveils preclinical therapy for Fuchs dystrophy and Bullous Keratopathy - Traders Union
Lineage Cell Therapeutics (LCTX) Expands with New Corneal Cell T - GuruFocus
Lineage targets corneal disease with lab-made cells amid donor shortage - Stock Titan
[EFFECT] Lineage Cell Therapeu... | LCTX SEC FilingForm EFFECT - Stock Titan
Geopolitics Watch: Can Lineage Cell Therapeutics Inc scale operations efficiently2026 Intraday Action & Verified Stock Trade Ideas - baoquankhu1.vn
LCTX SEC FilingsLineage Cell The 10-K, 10-Q, 8-K Forms - Stock Titan
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
Insider Buying: Brian Culley Acquires 15,000 Shares of Lineage C - GuruFocus
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) CEO Brian Culley Purchases 15,000 Shares - MarketBeat
Lineage Cell Therapeutics (LCTX) CEO adds 15,000 shares in open-market purchase - Stock Titan
Lineage Cell Therapeutics, Inc. Files Form 8-K for At-The-Market Offering – Key Company and Security Information (LCTX, NYSEAMER) 232425 - Minichart
Lineage extends cash runway into Q2 2028 while advancing OpRegen and new pipeline programs - MSN
Lineage Cell Therapeutics files prospectus supplement for up to $60 million share offering - Investing.com
Lineage Therap Expands ATM Equity Offering Capacity - TipRanks
Lineage Cell Therapeutics files prospectus supplement for up to $60M ATM equity offering - TradingView
Lineage Cell Therapeutics (LCTX) files $100M shelf to issue shares, debt, warrants - Stock Titan
Lineage Cell (NYSE: LCTX) files supplement for $60M ATM shares - Stock Titan
Ligand Pharmaceuticals (LCTX) raises ATM ceiling to $60M with B. Riley - Stock Titan
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2025 earnings call transcript - MSN
US Market Wrap: Is Klotho Neurosciences Inc gaining market shareGap Down & Daily Technical Forecast Reports - baoquankhu1.vn
H.C. Wainwright Maintains Buy on Lineage Cell Therapeutics (LCTX) Mar 2026 - Meyka
Lineage Cell Therapeutics Extends Runway Amid R&D Surge - TipRanks
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Why Lineage Cell Therapeutics Inc. stock could outperform in 2026Portfolio Performance Summary & Free Verified High Yield Trade Plans - Naître et grandir
Regulatory Risks Loom for Lineage Cell Therapeutics as Legacy Pluripotent Cell Lines Face Potential Compliance Challenges - TipRanks
Can Lineage Cell Therapeutics Inc. stock resist market sell offsQuarterly Growth Report & Long Hold Capital Preservation Plans - Naître et grandir
Risk Off: Is Lineage Cell Therapeutics Inc stock overvalued or fairly pricedJuly 2025 Momentum & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Lineage Cell (LCTX) grants CFO 1.05M employee stock options - Stock Titan
Lineage Cell Therapeutics (LCTX) grants 900,000 stock options to General Counsel - Stock Titan
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Raised to $3.00 - MarketBeat
LCTX Stock Rating Maintained as Buy; Price Target Raised by D. B - GuruFocus
H.C. Wainwright reiterates Buy on Lineage Cell stock, $9 target - Investing.com South Africa
Lineage Cell Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Lineage Cell Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Lineage Cell Therapeutics (LCTX) Extends Cash Runway with Positi - GuruFocus
Earnings Call Summary | Lineage Cell Therapeutics(LCTX.US) Q4 2025 Earnings Conference - 富途牛牛
Lineage Cell Therapeutics earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Investing News Network
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides B - PharmiWeb.com
Lineage Cell (LCTX) Reports Break-Even Earnings for Q4 - Yahoo Finance
Lineage Cell Therapeutics (LCTX) Sees Revenue Surge in Q4 - GuruFocus
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS - MarketBeat
Lineage Cell Therapeutics posts fourth quarter and full year 2025 financial results ahead of update call - Traders Union
Lineage Cell Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
LCTX,BTX Volatility & Greeks - Finviz
Lineage Cell Therapeutics (LCTX) Q4 Earnings Preview: Key Expectations - GuruFocus
A Look Ahead: Lineage Cell Therapeutics's Earnings Forecast - Benzinga
LCTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Lineage Cell Therapeutics (LCTX) to Release Earnings on Monday - MarketBeat
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):